Veterinary Assistive Reproduction Technology Market Report 2026

The veterinary assistive reproduction technology market size has grown strongly in recent years. It will grow from $3.63 billion in 2025 to $3.91 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to reliance on natural breeding, limited access to reproductive technologies, growing demand for high-quality livestock, traditional veterinary services, low awareness of genetic improvement programs.

The veterinary assistive reproduction technology market size is expected to see strong growth in the next few years. It will grow to $5.24 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to adoption of ai, ivf, and embryo transfer technologies, expansion of animal breeding centers, increasing focus on genetic improvement, growth of veterinary clinics offering ART services, integration of digital reproductive management solutions. Major trends in the forecast period include expansion of embryo transfer and ivf services, increasing use of frozen and fresh semen across species, growth of genetic testing services in animal breeding, adoption of ultrasound and advanced reproductive instruments, rising demand for hormonal treatment and ai kits.

The rising demand for livestock is expected to drive the growth of the veterinary assistive reproduction technology (VART) market going forward. Increasing demand for livestock is fueled by consumer expectations for superior taste and nutritional value, as well as advancements in breeding technologies that produce animals with desirable traits. VART improves livestock breeding efficiency by supporting fertilization and embryo development, resulting in enhanced genetic improvement and productivity. For example, in August 2024, according to the Agriculture and Horticulture Development Board, a UK-based levy board representing farmers, as of December 2023, the number of female cattle older than 24 months increased by 5,000 head from the previous year, reaching a total of 235,000. Therefore, the growing demand for livestock is driving the veterinary assistive reproduction technology market.

Leading players in the veterinary assistive reproduction technology market are focusing on innovative products, such as advanced chelated minerals for the reproductive health of dairy animals, to improve reproductive efficiency and enhance overall livestock health and productivity. Advanced chelated minerals are dietary supplements formulated to improve fertility and reproductive performance in dairy cattle. For example, in July 2023, Rodec Pharma Limited, an India-based manufacturer of veterinary medicines, introduced CMIN H8, an advanced chelated mineral feed designed to enhance the reproductive health of dairy animals. This product addresses common reproductive challenges in the dairy industry, such as infertility and other health-related issues that can affect productivity. By providing essential minerals in a chelated form, CMIN H8 improves nutrient bioavailability, ensuring optimal support for the reproductive systems of dairy animals.

In March 2024, Calibre Scientific, a US-based life sciences company, acquired Microm UK for an undisclosed amount. Through this acquisition, Calibre Scientific aims to expand its portfolio in assisted reproductive technologies, strengthen its commitment to reproductive health, grow its customer base in key markets, and introduce complementary consumable products to its existing assisted reproductive technology (ART) instruments. Microm UK is a UK-based provider of assisted reproductive technology solutions.

Major companies operating in the veterinary assistive reproduction technology market are Zoetis Inc., Merck Animal Health, IDEXX Laboratories Inc., Neogen Corporation, Genus plc, ABS Global Inc., Cryoport Inc., Minitube International Inc., Semex Alliance, Select Sires Inc., Cogent Breeding Ltd., Trans Ova Genetics LLC, Viking Genetics, Vytelle Inc., Agtech Inc., IMV Technologies, MOFA Global Inc., Emlab Genetics, Avantea Srl, Alta Genetics Inc., Aberekin S.L.

North America was the largest region in the veterinary assistive reproduction technology market in 2025. The regions covered in the veterinary assistive reproduction technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary assistive reproduction technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the veterinary assistive reproduction technology market by increasing costs for imported instruments, semen, kits, and consumables. Segments such as embryo transfer instruments, AI kits, and frozen semen are most affected, particularly in regions like North America and Europe. Despite higher costs, tariffs encourage local manufacturing, promote development of cost-effective reproductive solutions, and drive innovation in genetic testing and reproductive management services.

The veterinary assistive reproduction technology market research report is one of a series of new reports that provides veterinary assistive reproduction technology market statistics, including veterinary assistive reproduction technology industry global market size, regional shares, competitors with a veterinary assistive reproduction technology market share, detailed veterinary assistive reproduction technology market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary assistive reproduction technology industry. This veterinary assistive reproduction technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary assistive reproduction technology encompasses a range of advanced techniques and tools designed to enhance reproductive success in animals. These methods include artificial insemination, embryo transfer, and in vitro fertilization, all aimed at improving breeding efficiency, managing genetics, and increasing reproductive success across various animal species.

The primary categories of veterinary assistive reproduction technology include services, semen, instruments, and kits and consumables. The services involve procedures such as artificial insemination, embryo transfer, and in vitro fertilization, applied to animals such as cattle, pigs, sheep, goats, horses, and others. These services are distributed through both private and public channels. The technology supports various end users, including veterinary clinics and hospitals, animal breeding centers, research institutions, and universities.

The veterinary assistive reproduction technology market includes revenues earned by entities by providing services such as semen cryopreservation, estrus synchronization, ovum pick-up (OPU), cloning, genetic preservation, and animal breeding. The market value includes the value of related goods sold by the service provider or included within the service offering. The veterinary assistive reproduction technology market also consists of sales of embryo transfer kits, semen collection systems, cryopreservation equipment, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.